We present a clinical case report regarding recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine. Atrial fibrillation represents the most common sustained cardiac arrhythmia, occurring in 1-2% of the general population and characterized by seemingly disorganized atrial depolarizations without effective atrial contraction. Several mechanisms determine this arrhythmia; in particular remodelling (structural, mechanical and electrical alteration related to atrial fibrillation). The pro-arrhythmic effect of azathioprine may be evaluated during immunosuppressive therapy to be aware of this serious but reversible adverse effect.
Case report
We present the case of a 62-year-old Caucasian woman with ulcerative colitis (UC) treated with immunosuppressive therapy with azathioprine (AZ). The patient had suffered from this condition for over 4 years and had received various treatments (salicylic derivatives and oral corticosteroids). The AZ treatment had been started 2 years earlier, but was stopped after a few months because the patient reported palpitations and dyspnoea. The ECG showed fast atrial fibrillation. For this reason the patient was admitted to the Cardiology Unit and underwent pharmacological cardioversion with intravenous amiodarone to restore sinus rhythm. No abnormal cardiovascular signs were found, and she was in sinus rhythm (65 beats/min) with a normal blood pressure of 130/80 mmHg. An ECG on admission and chest x-ray were normal. Three days later, after pharmacological cardioversion, AZ was reintroduced for the treatment of U'C, One month later the patient showed another fast atrial fibrillation (AF) ( Fig. 1 ). AZ was immediately stopped, and the AF resolved within five days of bed rest with only anticoagulant therapy. Tests of thyroid function yielded normal results, and serum electrolyte concentrations and a later ECG ( Fig. 2 ) were normal.
We found two other cases in literature (1-2) of similar onset of AF after AZ use for the treatment of UC, although some confounding elements in these episodes make the possible causal relationship between the drug and this adverse event uncertain. population characterized by seemingly disorganized atrial depolarizations without effective atrial contraction. AF prevalence is estimated to at least double in the next 50 years, and it is associated with increased rates of death, stroke and other thromboembolic events, heart failure and hospitalizations, degraded quality of life, reduced exercise capacity, and left ventricular dysfunction (3).
Any kind of structural heart disease may trigger a slow but progressive process of structural remodelling in both the ventricles and the atria. In the atria, proliferation and differentiation of fibroblasts into myofibroblasts and enhanced connective tissue deposition and fibrosis are the hallmarks of this process. Structural remodelling results in electrical dissociation between muscle bundles and local conduction heterogeneities facilitating the initiation and perpetuation of AF. This electroanatomical substrate permits multiple small re-entrant circuits that can stabilize the arrhythmia.
There are several mechanisms that determine this arrhythmia, such as genetic predisposition (AF has a familial component, especially AF of early onset), structural abnormalities which allow the development of AF (extracellular matrix alterations, myocyte alterations, microvascular changes, and endocardial remodelling [endomyocardial fibrosis]), predisposing structural factors (the role of the Bachmann's bundle and frequency gradients between the left and right atrium), and electrophysiological factors (heterogeneous refractory periods favor the fibrillary conduction). Many triggers such as abnormal electrical activity (pulmonary vein ectopic foci), and modulating factors (autonomic nervous system, increased vagal tone shortens atrial refractory periods) may set off AF. Finally, there are three types of atrial remodeling: structural, contractile, electrical. They are interrelated and contribute to maintaining the AF (4).
The "remodeling" term summarizes structural, mechanical and electrical alteration related to AF. The final consequences are represented by the development of atrial fibrosis and inflammatory subclinical post-surgical state (atrial myocarditis). Finally, several factors such activation of reninangiotensin system, adrenergical activation, subclinical inflammation, fibrosis, accumulation of intracellular Ca++, and atrial apoptosis may contribute to determine an arrhythmic substrate at the basis of AF (5) .
AZ is an immunosuppressant prodrug agent, which is converted in the body to its active form called 6-mercaptopurine, widely used in the treatment of Uc. Like other immunosuppressants, AZ suppresses the proliferation of T and B lymphocytes, types of white blood cells that are part of the immune system and body defender ( infectious diseases and foreign materials). Toxic effects of this drug include depression of bone marrow, hepatotoxicity, gastrointestinal upsets, reduced resistance to infection, malignant tumors, and teratogenicity (6-7).
The primary mechanism of AF in patients treated with AZ is unclear and in literature few reports of cardiac side effects of AZ treatment are reported. Episodes of AF in normal heart subjects can be worsened by drugs, alcohol, and nicotine, as well as by non-cardiac events such as surgery, pneumonia, bums, mediastinal carcinoma, lymphoma, pulmonary embolism, and renal and biliary colic. There was no precipitating event in our patient other than the administration of AZ, and the heart was clinically and electrocardiographically normal before and after the episode. The pro-arrhythmic effect ofAZ may be evaluated during immunosuppressive therapy to be aware of this serious but reversible adverse effect.
